Show simple item record

dc.contributor.authorTonon, André Comiranpt_BR
dc.contributor.authorPilz, Luísa Klauspt_BR
dc.contributor.authorMarkus, Regina Pekelmannpt_BR
dc.contributor.authorHidalgo, Maria Paz Loayzapt_BR
dc.contributor.authorElisabetsky, Elainept_BR
dc.date.accessioned2022-06-15T04:42:31Zpt_BR
dc.date.issued2021pt_BR
dc.identifier.issn1664-0640pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/240285pt_BR
dc.description.abstractDaily rhythm of melatonin synchronizes the body to the light/dark environmental cycle. Several hypotheses have been raised to understand the intersections between melatonin and depression, in which changes in rest-activity and sleep patterns are prominent. This review describes key experimental and clinical evidence that link melatonin with the etiopathology and symptomatology of depressive states, its role in the follow up of therapeutic response to antidepressants, as well as the clinical evidence of melatonin as MDD treatment. Melatonin, as an internal temporal cue contributing to circadian organization and best studied in the context of circadian misalignment, is also implicated in neuroplasticity. The monoaminergic systems that underly MDD and melatonin production overlap. In addition, the urinary metabolite 6-sulfatoxymelatonin (aMT6) has been proposed as biomarker for antidepressant responders, by revealing whether the blockage of noradrenaline uptake has taken place within 24 h from the first antidepressant dose. Even though animal models show benefits from melatonin supplementation on depressive-like behavior, clinical evidence is inconsistent vis-à-vis prophylactic or therapeutic benefits of melatonin or melatonin agonists in depression. We argue that the study of melatonin in MDD or other psychiatric disorders must take into account the specificities of melatonin as an integrating molecule, inextricably linked to entrainment, metabolism, immunity, neurotransmission, and cell homeostasis.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofFrontiers in psychiatry. Lausanne. Vol. 12 (2021), 638981, 13 p.pt_BR
dc.rightsOpen Accessen
dc.subjectBiomarcadorespt_BR
dc.subjectPsychiatryen
dc.subjectMood disorderen
dc.subjectTranstornos do humorpt_BR
dc.subjectRitmo circadianopt_BR
dc.subjectNeuropsychaitric disordersen
dc.subjectBehavioren
dc.subjectCronobiologiapt_BR
dc.subjectBiological rhythmsen
dc.subjectDepressãopt_BR
dc.subjectMelatoninapt_BR
dc.subjectChronobiologyen
dc.subjectModelos animaispt_BR
dc.subject6-sulfatoxymelatonin (aMT6s)en
dc.subjectEstudo clínicopt_BR
dc.subjectBiomarkeren
dc.titleMelatonin and depression : a translational perspective from animal models to clinical studiespt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001139782pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record